Table 12.

Five Kinase Inhibitors for CML. CML is classified by phase, CP, AP, BP, or by number of treatment lines, i.e., newly diagnosed (new) or resistant or intolerant (R/I). New CP = newly diagnosed chronic phase, R/I CP= refractory or intolerant chronic phase, CCyR=complete cytogenetic response, MCyR= major cytogenetic response, CHR=complete hematologic response. Serious fluid retention= pleural, pericardial, peritoneal effusions. CHF=congestive heart failure.

	Imatinib	Dasatinib	Nilotinib	Bosutinib	Ponatinib
CP	1st line	1st, 2nd, 3rd line	1st, 2nd, 3rd line	2nd, 3rd line	2nd, 3rd line
AP	1st line	2nd, 3rd line	2nd, 3rd line	2nd, 3rd line	2nd, 3rd line
BP	1st line	2nd, 3rd line	not studied	2nd, 3rd line	2nd, 3rd line
Ph+ALL	Refractory ALL (first line with concurrent chemo)	2nd, 3rd line (first line with concurrent chemo)	not studied	not studied	2nd, 3rd line
T315I	resistant	resistant	resistant	resistant	sensitive
New CCyR	75% at 84 months	77%) vs 66%at 12 months£	80% vs 65% at 12 months£	not indicated	not indicated
imatinib R/I CP,MCyR	NA	63% at 22 months	51% at 18 mos	27% at 5.5 months€; (as 3rd line)	49% at 10 months
AP, CHR	38% at 18 months	47% at 6 months	30% at 18 mos	30% at 11 months€	47% at 10 months
BP, CHR	7% at 18 months	17-21% at 6 months	not studied	15% at 11 months€	21% at 10 months
food	with	without	without	with	with/without
serious fluid retention	G1-4 7% in new CP	G1-4 14% in new CP	G1-4 1% in new CP	G3≥ 3% in R/I all phases	10% in R/I all phases G3≥ 1% in R/I CP
all Grade CHF	0.7%in new CP	2%in new CP			6% in R/I
G3-4 lipase			7% in new CP 18% in R/I CP check monthly	8% in R/I CP	15% in combined R/I, AP, BP, ALL check biweekly × 2 months then monthly

NA=not applicable. €=at data cut off time, otherwise all other months are at median duration of treatment. £=compared to imatinib.